Clinical Trials in Washington

Showing 3521-3540 of 6,196 trials

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

NCT02541565

This pilot phase I trial studies the side effects of pembrolizumab and combination chemotherapy in treating patients with previously untreated diffuse large B-cell lymphoma or grade 3b follicular lymphoma. Monoclonal antibodies, such as pembrolizumab and rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab together with combination chemotherapy may be with a better treatment for diffuse large B-cell lymphoma or follicular lymphoma.

Composite LymphomaGrade 3b Follicular LymphomaStage I Diffuse Large B-Cell Lymphoma+7 more

University of Washington30 participantsStarted Nov 2015

Seattle, Washington, United States

COMPLETEDPhase 242 miles

Single Arm on the Tolerability of Weekly Nab-paclitaxel

NCT01702844

The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell lung cancer (NSCLC)

Non Small Cell Lung Cancer (NSCLC)

UNC Lineberger Comprehensive Cancer Center42 participantsStarted Jun 2013

Fayetteville, Arkansas, United States • Chapel Hill, North Carolina, United States • Raleigh, North Carolina, United States +5 more locations

Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Diffuse Large B-cell Lymphoma or Grade 3b Follicular Lymphoma

Single Arm on the Tolerability of Weekly Nab-paclitaxel

Find Trials by Condition in Washington

Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis

BARD® Study of LIFESTREAM™ Balloon Expandable Covered Stent Treating Iliac Arterial Occlusive Disease

Doppler Flow Wires in Cerebral Angiography

EVOLVE Short DAPT Study

Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer

ENTYVIO in Bio-naive Patients With Moderate/Severe Crohn's Disease (CD) in Daily Practice

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

PROMINENT-Eye Ancillary Study (Protocol AD)

Dose-response Relationship Study of S42909 on Leg Ulcer Healing

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001